These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34619232)

  • 21. SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients.
    Basic-Jukic N; Ivo J
    Transpl Infect Dis; 2021 Aug; 23(4):e13628. PubMed ID: 33915005
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of Risk Factors for a Low Immune Response to Messenger RNA COVID-19 Vaccine in Kidney Transplant Recipients and Differences Between Second and Third Dose.
    Panarese A; Canossi A; Fabiani R; Lupi D; Maccarone D; Pace P; Parzanese I; Martinez V; Lancione L; Savino V; Cacchioni C; Cervelli C; Papola F; Pisani F
    Transplant Proc; 2022 Dec; 54(10):2646-2651. PubMed ID: 36400591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Should We Consider Intradermal Vaccination?
    Wijtvliet V; Wissing KM; Abramowicz D; Ledeganck KJ
    J Am Soc Nephrol; 2022 Apr; 33(4):869-870. PubMed ID: 35165123
    [No Abstract]   [Full Text] [Related]  

  • 24. Significant humoral response to mRNA COVID-19 vaccine in kidney transplant recipients with prior exposure to SARS-CoV-2: the COViNEPH Project.
    Dębska-Ślizień A; Muchlado M; Ślizień Z; Kubanek A; Piotrowska M; Dąbrowska M; Bzoma B; Konopa J; Renke M; Biedunkiewicz B; Tylicki L
    Pol Arch Intern Med; 2022 Jan; 132(1):. PubMed ID: 34809419
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review.
    Akyol M; Çevik E; Ucku D; Tanrıöver C; Afşar B; Kanbay A; Covic A; Ortiz A; Basile C; Kanbay M
    Tuberk Toraks; 2021 Dec; 69(4):547-560. PubMed ID: 34957748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients.
    Ducloux D; Bamoulid J; Chabannes M; Colladant M; Munshi A; Roubiou C; Seibel J; Tachikart A; Yannaraki M; Crepin T; Courivaud C
    J Infect; 2022 Mar; 84(3):e34-e35. PubMed ID: 35074507
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of severe COVID-19 despite full vaccination with mRNA-1273 SARS-CoV-2 vaccine (Moderna) in a kidney transplant recipient.
    Chang KM; Berlinrut I; Wallach FR
    Transpl Infect Dis; 2021 Oct; 23(5):e13710. PubMed ID: 34339083
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical consequences of the suboptimal effect of messenger RNA-based SARS-CoV-2 vaccine in renal transplant recipients.
    Basic-Jukic N
    Ther Apher Dial; 2022 Feb; 26(1):248-249. PubMed ID: 34076943
    [No Abstract]   [Full Text] [Related]  

  • 30. Protection against SARS-CoV-2 Variants with COVID-19 Vaccination in Kidney Transplant Recipients.
    Bertrand D; Candon S
    Clin J Am Soc Nephrol; 2022 Jan; 17(1):3-5. PubMed ID: 34937770
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor Serologic Response to 2 Doses of an mRNA-based SARS-CoV-2 Vaccine in Lung Transplant Recipients.
    Hoffman TW; Meek B; Rijkers GT; van Kessel DA
    Transplantation; 2022 Jan; 106(1):e103-e104. PubMed ID: 34699459
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients.
    Toniutto P; Aghemo A; Grossi P; Burra P;
    Dig Liver Dis; 2021 Oct; 53(10):1232-1234. PubMed ID: 34393073
    [No Abstract]   [Full Text] [Related]  

  • 34. REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme.
    Ducloux D; Courivaud C
    Kidney Int; 2022 Mar; 101(3):645-646. PubMed ID: 34995651
    [No Abstract]   [Full Text] [Related]  

  • 35. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients.
    Dolff S; Korth J; Jahn M; Kribben A; Witzke O; Wilde B
    Transplantation; 2021 Sep; 105(9):e99. PubMed ID: 33966023
    [No Abstract]   [Full Text] [Related]  

  • 37. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.
    Rincon-Arevalo H; Choi M; Stefanski AL; Halleck F; Weber U; Szelinski F; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Potekhin A; Chen Y; Burmester GR; Eckardt KU; Guerra GM; Durek P; Heinrich F; Ferreira-Gomes M; Radbruch A; Budde K; Lino AC; Mashreghi MF; Schrezenmeier E; Dörner T
    Sci Immunol; 2021 Jun; 6(60):. PubMed ID: 34131023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver injury after mRNA-based SARS-CoV-2 vaccination in a liver transplant recipient.
    Dumortier J
    Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101743. PubMed ID: 34146727
    [No Abstract]   [Full Text] [Related]  

  • 39. COVID-19 in Kidney Transplant Recipients Vaccinated With Oxford-AstraZeneca COVID-19 Vaccine (Covishield): A Single-center Experience From India.
    Meshram HS; Kute VB; Shah N; Chauhan S; Navadiya VV; Patel AH; Patel HV; Engineer D; Banerjee S; Rizvi J; Mishra VV
    Transplantation; 2021 Sep; 105(9):e100-e103. PubMed ID: 34049359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients.
    Del Bello A; Abravanel F; Marion O; Couat C; Esposito L; Lavayssière L; Izopet J; Kamar N
    Am J Transplant; 2022 Jan; 22(1):322-323. PubMed ID: 34331842
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.